A share price of Corvus Pharmaceuticals Inc [CRVS] is currently trading at $5.44, up 4.21%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The CRVS shares have gain 6.67% over the last week, with a monthly amount glided 15.74%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Corvus Pharmaceuticals Inc [NASDAQ: CRVS] stock has seen the most recent analyst activity on January 02, 2025, when H.C. Wainwright initiated its Buy rating and assigned the stock a price target of $11. Previously, Oppenheimer started tracking the stock with Outperform rating on August 18, 2023, and set its price target to $7. Cantor Fitzgerald started tracking the stock assigning a Overweight rating and suggested a price target of $10 on May 27, 2021. Mizuho downgraded its rating to a Neutral and reduced its price target to $4 on February 10, 2021. In a note dated May 29, 2019, ROTH Capital initiated an Buy rating and provided a target price of $6 on this stock.
Corvus Pharmaceuticals Inc experienced fluctuations in its stock price throughout the past year between $1.30 and $10.00. Currently, Wall Street analysts expect the stock to reach $12.5 within the next 12 months. Corvus Pharmaceuticals Inc [NASDAQ: CRVS] shares were valued at $5.44 at the most recent close of the market. An investor can expect a potential return of 129.78% based on the average CRVS price forecast.
Analyzing the CRVS fundamentals
Gross Profit Margin for this corporation currently stands at 0.71% with Operating Profit Margin at -102.01%, Pretax Profit Margin comes in at -231.03%, and Net Profit Margin reading is -231.03%. To continue investigating profitability, this company’s Return on Assets is posted at -0.97, Equity is -1.68 and Total Capital is -2.02. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.03.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 5.27 points at the first support level, and at 5.09 for the second support level. However, for the 1st resistance point, the stock is sitting at 5.61, and for the 2nd resistance point, it is at 5.77.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Corvus Pharmaceuticals Inc [NASDAQ:CRVS] is 0.92. As well, the Quick Ratio is 0.92, while the Cash Ratio is 0.1.
Transactions by insiders
Recent insider trading involved Jones William Benton,, that happened on May 06 ’24 when 20000.0 shares were purchased. President and CEO, MILLER RICHARD A MD completed a deal on May 06 ’24 to buy 0.58 million shares.
